The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer

Archive ouverte

Byrne, Julianne | Alessi, Daniela | Allodji, Rodrigue | Bagnasco, Francesca | Bárdi, Edit | Bautz, Andrea | Bright, Chloe | Brown, Morven | Diallo, Ibrahima | Lieke Feijen, Elizabeth A M | Fidler, Miranda | Frey, Eva | Garwicz, Stanislaw | Grabow, Desiree | Gudmundsdottir, Thorgerdur | Hagberg, Oskar | Harila-Saari, Arja | Hau, Eva | Haupt, Riccardo | Hawkins, Mike | Jakab, Zsuzsanna | Jankovic, Momcilo | Kaatsch, Peter | Kaiser, Melanie | Kremer, Leontien C.M. | Kuehni, Claudia | Kuonen, Rahel | Ladenstein, Ruth | Lähteenmäki, Päivi Maria | Levitt, Gill | Linge, Helena | Llanas, Damien | Michel, Gisela | Morsellino, Vera | Mulder, Renee | Reulen, Raoul | Ronckers, Cécile | Sacerdote, Carlotta | Skinner, Roderick | Steliarova-Foucher, Eva | van der Pal, Helena | de Vathaire, Florent | Vũ Bezin, Giao | Wesenberg, Finn | Wiebe, Thomas | Winter, David | Winther, Jeanette Falck | Witthoff, Elise | Zadravec Zaletel, Lorna | Hjorth, Lars

Edité par CCSD ; Elsevier -

International audience. Background: Second malignant neoplasms and cardiotoxicity are among the most serious and frequent adverse health outcomes experienced by childhood and adolescent cancer survivors (CCSs) and contribute significantly to their increased risk of premature mortality. Owing to differences in health-care systems, language and culture across the continent, Europe has had limited success in establishing multi-country collaborations needed to assemble the numbers of survivors required to clarify the health issues arising after successful cancer treatment. PanCareSurFup (PCSF) is the first pan-European project to evaluate some of the serious long-term health risks faced by survivors. This article sets out the overall rationale, methods and preliminary results of PCSF.Methods: The PCSF consortium pooled data from 13 cancer registries and hospitals in 12 European countries to evaluate subsequent primary malignancies, cardiac disease and late mortality in survivors diagnosed between ages 0 and 20 years. In addition, PCSF integrated radiation dosimetry to sites of second malignancies and to the heart, developed evidence-based guidelines for long-term care and for transition services, and disseminated results to survivors and the public.Results: We identified 115,596 individuals diagnosed with cancer, of whom 83,333 were 5-year survivors and diagnosed from 1940 to 2011. This single data set forms the basis for cohort analyses of subsequent malignancies, cardiac disease and late mortality and case-control studies of subsequent malignancies and cardiac disease in 5-year survivors.Conclusions: PCSF delivered specific estimates of risk and comprehensive guidelines to help survivors and care-givers. The expected benefit is to provide every European CCS with improved access to care and better long-term health.

Suggestions

Du même auteur

Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup

Archive ouverte | Allodji, Rodrigue | CCSD

International audience. Background: Survivors of childhood cancers are at risk of developing subsequent primary leukaemias (SPLs), but the long-term risks beyond 20 years of treatment are still unclear. We investiga...

The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries

Archive ouverte | Grabow, Desiree | CCSD

International audience. Childhood cancer survivors face risks from a variety of late effects, including cardiac events, second cancers, and late mortality. The aim of the pan-European PanCare Childhood and Adolescen...

Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study

Archive ouverte | Reulen, Raoul | CCSD

International audience. Background Survivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We inves...

Chargement des enrichissements...